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gd T cells are important contributors to innate
immunity against cancer, but their regulatory
role in controlling immune responses remains
largelyunknown.Herewe report that adominant
gd1 T cell population among lymphocytes infil-
trating breast tumors possessed a potent ability
to suppress naive and effector T cell responses
and to block thematuration and function of den-
dritic cells. Adoptive cotransfer experiments
demonstrated their in vivo suppressive activity.
However, their immunosuppressive activity
could be reversed by human Toll-like receptor
(TLR) 8 ligands both in vitro and in vivo. siRNA-
mediated knockdown experiments revealed
thatMyD88, TRAF6, IKKa IKKb, and p38amole-
cules in gd1 cells were required for these cells
to respond to TLR8 ligands, whereas TAK1,
JNK, and ERK molecules did not appear to be
involved in functional regulation. These results
provide new insights into the regulatory mecha-
nisms of tumor-specific gd T cells and identify
a unique TLR8 signaling pathway linking to their
functional regulation.
INTRODUCTION
T cells play an essential role in the immunosurveillance and
destruction of tumor cells, but attempts to translate this
knowledge into clinically effective immunotherapies have
met with only limited success (Dunn et al., 2004; Rosen-
berg et al., 2004). One of the major impediments to this
goal is the activity of regulatory T (Treg) cells at tumor sites,
which can markedly suppress immune responses and
induce immune tolerance (Curiel et al., 2004; Liyanage
et al., 2002; Wang et al., 2004, 2005; Woo et al., 2001).
Although CD4+ Treg cells have been extensively studied,
much less isknown about other subsets of Treg cells, some
of which have the potential to suppress immune responses334 Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc.(Hayday and Tigelaar, 2003; Sakaguchi, 2004; Shevach,
2002).
T cells expressing g and d T cell receptor (TCR) chains
with limited usage represent only a small subset (2%–3%)
within the total T cell population. In contrast to recognition
of antigens by ab T cells, gd T cells recognize antigens
directly without any requirement for antigen processing
and presentation or major histocompatibility complex
(MHC) molecules (Brenner et al., 1986; Shin et al., 2005).
Of the two major subsets of human gd T cells, Vg2Vd2
(also known as Vg9Vd2, collectively designated Vd2) T
cells predominate in the peripheral blood and respond to
microbial infections by recognizing small nonpeptide mol-
ecules (Bukowski et al., 1999; Constant et al., 1994; Eberl
et al., 2004; Modlin et al., 1989). The other major subset,
Vd1 T cells (also called intraepithelial lymphocytes, or
IELs), comprises 70%–90% of the gd T cells in epithelial
tissues and may recognize either MHC class I-related
chain A or B (MICA or MICB), which are induced on epithe-
lial cells and tumor cells by stress or structural damage
(Groh et al., 1998; Hayday, 2000). However, MICA and
MICB, as well as distantly related ULBP proteins, may be
recognized via the activating receptor, NKG2D, which is
expressed not only on Vd1 T cells, but also on Vd2 T cells,
NK cells, and some ab T cells (Bauer et al., 1999). In con-
trast to human gd1 T cells, murine dendritic epidermal gd T
cells (DETCs) do not recognize bacterial phosphoanti-
gens, but they share the capacity to respond via NKG2D
to the MICA and ULBP ortholog, called Rae1 or H60, ex-
pressed by tumor cells, thus stimulating antitumor immu-
nity (Diefenbach et al., 2001; Groh et al., 1999). Addition-
ally, some murine gd TCRs engage another MHC Class
Ib gene product, T10 and T22, that may be overexpressed
by activated cells (Shin et al., 2005). Indeed, murine gd T
cells were shown to mediate resistance to squamous
cell carcinoma (Girardi et al., 2001). Collectively, these
findings have raised the intriguing possibility that gd T
cell recognition of MICA and MICB molecules on tumor
cells might be exploited to devise new strategies of cancer
immunotherapy (Boismenu and Havran, 1994; Girardi
et al., 2001; Hayday and Tigelaar, 2003; Jameson et al.,
2002).
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component of host innate immunity in response to tissue
stress or damage, malignancy, or infectious pathogens
(Havran, 2000; Hayday and Tigelaar, 2003; Jameson
et al., 2003), the function of gd T cells may be extremely
pleiotropic, harboring regulatory as well as effector poten-
tial (Hayday and Tigelaar, 2003; Pennington et al., 2005).
The possibility therefore exists that these gd T cells may
suppress immune responses.
In our previous study, we demonstrate that the suppres-
sive function of human naturally occurring CD4+ CD25+
Treg cells and tumor-derived antigen-specific CD4+ Treg
cells can be reversed by TLR8 signaling pathway (Peng
et al., 2005). This reversal effect does not require the
involvement of dendritic cells (DCs), but requires the acti-
vation of TLR8-MyD88-IRAK4 signaling pathway in Treg
cells for their functional reversal (Peng et al., 2005). Sev-
eral other studies show that TLR2 plays a critical role in re-
gulating the suppressive function of murine CD4+ CD25+
Treg cells (Liu et al., 2006; Sutmuller et al., 2006a). Expres-
sion of various TLRs has been documented in both human
and murine Treg cells (Sutmuller et al., 2006b). However, it
is not clear whether human gd T cells also express TLRs.
More importantly, whether the suppressive function of
gd T cells can be regulated through TLR signaling remains
largely unknown.
In our recent efforts to establish tumor-specific T cells
from breast cancers, we unexpectedly identified a domi-
nant gd1 T cell population in the total population of
tumor-infiltrating lymphocytes (TILs). This prompted us to
characterize these tumor-specific gd1 T cells with regard
to their function and regulatory mechanisms. Here we
report that tumor-derived gd1 T cells possess the potent
capacity to suppress immune responses. Their immune-
suppressive function could be controlled via the TLR8
signaling pathway. Further studies revealed that MyD88,
TRAF6, IKKa, IKKb, or p38a molecules in gd1 T cells were
required for their functional reversal in response to TLR8
ligands, whereas TAK1, JNK, and ERK molecules were
not. These findings identify a natural pathophysiologic
involvement of human gd1 T cells in tumor immunity and
provide new insights into their regulatory mechanisms
for controlling their suppressive function.
RESULTS
gd1 T Cells Are a Dominant Tumor-Infiltrating
T Cell Population
We generated breast-tumor-derived tumor-infiltrating
lymphocytes (TILs) with the intent of identifying new breast
cancer antigens. Breast-tumor-derived TIL31 (BTIL31)
cells specifically recognized autologous breast cancer
cells (BC31) as detected by IFN-g secretion but did not
respond to allogeneic breast cancer cells (MCF-7, BC29,
BC30, and BC36), prostate cancer cells (PC263 and
PC267), melanoma cells (1363mel and 1359mel), 586
EBV-transformed B cells, or 293T cells (Figure 1A). Tumor
reactivity and specificity were observed for several T cell
clones established from the bulk BTIL31 population(Figure 1B), suggesting that BTIL31 and its clones are
T cells specific for breast tumors.
To determine the requirement for MHC molecule-
restricted T cell recognition by BTIL31, we performed a
T cell functional assay in the presence or absence of spe-
cific antibodies against MHC molecules. None of these
blocking antibodies could inhibit T cell recognition (Fig-
ures S1A and S1B in Supplemental Data available online),
indicating that unlike conventional CD4+ or CD8+ T cells,
these BTIL31 T cells do not require MHC-class I or II mol-
ecules for tumor recognition. FACS analysis revealed that
these cells were positive for CD3, CD8, CD56, and gd TCR
molecules, but negative for the ab TCR marker (Figure 1C),
suggesting that they were tumor-specific gd TCR-
expressing T cells. Theg9d2 subset is generally considered
a dominant population representing 3%–5% of the total
peripheral T cells, whereas Vd1 T cells reside mainly in
epithelial tissues and skin (Kabelitz et al., 2005). To deter-
mine the subtype of the BTIL31 T cells, we stained the bulk
BTIL31 line and its clones with a Vd1 or Vd2 antibody. More
than 95% of the T cells were positive for Vd1 but negative
for Vd2 antibody staining (Figure 1D), indicating that the
BTIL31 T cells are breast-tumor-specific gd1 T cells that
accumulate predominantly in breast-tumor tissues. To
determine whether these CD8+ T cells express CD8aa or
CDab molecules, we stained gd1 T cells as well as two
conventional CD8+ T cell lines (TIL1359-20 and BTIL29-
C1, which recognize antigens in the context of MHC class I
molecules) with CD8a and CD8b antibodies. These
human CD8+ gd1 T cells expressed CD8aa homodimer,
but not the CD8ab heterodimer usually expressed by
conventional T cells such as TIL1359-20 and BTIL29-
C1 (Figure 1E), suggesting that human CD8aa+ gd1 T
cells phenotypically resemble murine CD8aa+ gd T cells
(Hayday, 2000).
Prevalence of gd1 T Cells in Breast
and Prostate Cancer
To substatiate the high percentage of gd1 T cells observed
in Figure 1D, we analyzed TILs derived from breast tumors
established from an additional 10 breast cancer patients
and observed a high percentages of gd1 T cells among
TILs (7.2%–75.7%; mean 33.2%) (Figure 2A). To exclude
the possibility that the high percentage of gd1 T cells ob-
served in breast cancer-derived TILs was due to in vitro
cell culture, we first tested the prevalence of gd1 T cells
in other tumors such as prostate cancer and melanoma.
With the use of an identical culture condition and method,
we found that prostate-tumor-derived TILs also contained
high percentages of gd1 T cells in the total T cell popula-
tion (21.7%–96.3%; mean 40.1%), whereas among mela-
noma-derived TILs, the percentage was low (2.8%–7.5%;
mean 5.7%) (Figure 2B). Thus, elevated proportions of
gd1 T cells are prevalent in tumors originating from epithe-
lium, including breast and prostate cancers, but not in
melanoma, consistent with our previous extensive work
confirming a low percentage of gd T cells in melanoma-
derived TILs.Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc. 335
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Tumor-Specific Regulatory gd T CellsFigure 1. Generation and Characterization of Tumor-Specific gd1 T Cells
(A) Recognition of autologous breast-tumor cells by breast cancer-derived BTIL31 cells. BTIL31 T cells isolated from breast cancer tissues were
cocultured with autologous BC31 tumor cells as well as other tumor cell lines. After 18–24 hr culture, T cell reactivity was determined by measuring
IFN-g secretion in culture supernatants.
(B) Antigen specificity of BTIL31-derived T cell clones. T cell clones were established from the BTIL31 bulk cell line, and we tested their ability to
recognize BC31 tumor cells. Other cell lines served as controls.
(C) FACS analysis of surface markers of BTIL31 cells. BTIL31 cells were stained with mAb to CD3, CD4, CD8, CD56, CD161, TCR-ab, and TCR-gd
molecules. Isotype control antibodies served as negative controls.
(D) BTIL31 bulk and clones cells were predominantly gd1 T cells. BTIL31 cells and clones were stained with mAb to TCR-gd, TCR-Vd1, TCR-Vd2, and
TCR-Vg9.
(E) Expression of CD8aa homodimer by BTIL31 cells and its clones. BTIL31 cells and their clones were stained with CD8a and CD8bmAb. The stained
cells were then analyzed by FACS. Conventional CD8+ T cells (TIL1359-20 and BTIL 29-C1) served as positive controls for CD8b mAb.
Data are one of three experiments yielding similar results.We also isolated single-suspension cells from breast-
tumor (BT) samples and directly stained them with CD3
and gd TCR antibodies. FACS analysis gating on CD3+ T
cell population revealed high percentages (ranging from336 Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc.12% to 69%) of gd T cells in the total T cell population
from five breast-tumor samples analyzed (Figure 2C).
These data further suggest that an elevated percentage
of gd T cells in breast tumors is an intrinsic property of
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Tumor-Specific Regulatory gd T CellsFigure 2. Prevalence of gd1 T Cells Derived from Breast and Prostate Tumors
(A) High proportions of gd T cells in BTILs derived from breast tumors. The numbers are the percentage of gd1+ T cells in the total T cell population
established from breast cancer tissues.
(B) Percentages of gd1+ T cells in the total T cell population established from prostate cancer and melanoma.
(C) High proportions of gd T cells present in the T cell population directly isolated from breast tumors. FACS analysis was conducted after gating on the
CD3+ T population.
Data are representatives of three experiments yielding similar results.epithelium-derived tumors, rather than a result of cell
culturing in vitro.
TCR-Mediated Signal Is Critical for Tumor
Recognition by gd1 T Cells
Although gd1 T cells can recognize tumor cells without the
requirement for MHC class I and II molecules, we thought
it important to determine whether the recognition of tumor
cells by gd1 T cells requires TCR-mediated antigen stimu-
lation. To test this possibility, we cultured the gd1 T cells
with BC31 tumor cells in the presence or absence of anti-
bodies against MHC class I, class II, NKG2D, MICA,MICB, gd, or ab TCR molecules. The recognition of tumor
cells by BTIL31 gd1 T cells was completely blocked by a
TCR gd antibody, but only partially blocked by a NKG2D
antibody, either alone or in combination with MICA and
MICB antibody. In contrast, little or no inhibition was ob-
served with anti-MICA, anti-MICB, anti-CD1d, anti-MHC
class I, anti-MHC class II, or control antibodies (Figure 3A).
These results suggest that tumor recognition by BTIL31
gd1 T cells requires interaction between TCR and antigens
expressed by tumor cells, whereas NKG2D may enhance
T cell recognition by interacting with MICA. To test whether
interaction between NKG2D and MICA and MICB mayImmunity 27, 334–348, August 2007 ª2007 Elsevier Inc. 337
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Tumor-Specific Regulatory gd T CellsFigure 3. Recognition of Tumor Cells by BTIL31 T Cells
(A) Requirement of TCR-mediated signal in T cell recognition of tumor cells. IFN-g release from T cells was determined from the supernatants of
BTIL31 and BC31 tumor cell coculture in the presence of control antibody or antibodies against TCR, NK-G2D, MHC class I, class II, MICA, and
MICB molecules.
(B) FACS analysis for expression of NKG2D and ULBP molecules by T cells and tumor cells. BTIL31 T cells were stained with anti-NK-G2D, and
breast-tumor cell lines (BC30, BC31, and MCF-7) were stained with antibodies against MICA, MICB, ULBP-1, ULBP2, or ULBP3 molecules. The
stained cells were then analyzed by FACS.
Data are one of three experiments yielding similar results.function as a costimulatory signal, we evaluated the
expression of NKG2D on T cells and MICA and MICB on
tumor cells by FACS analysis and showed that although
gd1 T cells expressed NKG2D molecules, three breast-
tumor cell lines were negative for MICA or MICB (Fig-
ure 3B). Because NKG2D may interact with the ULBP
molecules of MICA and MICB paralog, we stained breast-
tumor cells with anti-ULBP1, anti-ULBP2, and anti-ULBP3,
and we found that indeed these breast-tumor cell lines
expressed ULBP1, ULBP2, and ULBP3 molecules. Taken
together, these results indicate that the interaction be-
tween the TCR and antigens expressed on tumor cells is
necessary and sufficient for T cell activation, whereas the
interaction between NKG2D and ULBP enhances tumor-
cell recognition by T cells.
Tumor-Specific gd1 T Cells Suppress Naive
and Effector T Cell Function
Given that tumor cells can grow even in the presence of up
to 95% tumor-specific gd1 T cells, it is clear that gd1 T
cells fail to eliminate these tumor cells. Instead, the grow-
ing tumor may drive the expansion of gd1 T cells through
tumor antigen-mediated activation, raising the possibility
of a negative regulatory function for tumor-derived gd1338 Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc.T cells. Thus, we reasoned that these tumor-derived gd1
T cells might play a role in inhibiting immune responses
against tumor cells. To test this possibility, we performed
a proliferation assay by using anti-CD3-(OKT3)-coated
plates without APCs to determine their function (Peng
et al., 2005). We found that the bulk BTIL31 cell line and
its clones strongly inhibited the proliferation of naive
T cells (Figure 4A). In contrast, gd2 T cells isolated from
normal PBMCs enhanced, rather than inhibited, the prolif-
eration of naive T cells in response to anti-CD3 stimulation.
gd1 T cell-mediated inhibition was also observed for naive
CD8+ T cells as well as gd2 effector T cells isolated from
PBMCs (Figures S2A and S2C). To test whether other
gd1 T cells derived from breast tumors possess suppres-
sive function, we purified gd1 T cells from bulk TILs by
FACS sorting after staining with gd1 antibody and as-
sessed their ability to suppress naive T cell proliferation
(Figure 4B). Like BTIL31 gd1 T cells, most breast-tumor-
derived gd1 T cells possessed suppressive activity (Fig-
ure 4B). These results strongly suggest that the majority
of breast-tumor-derived gd1 T cells possess a potent
suppressive function.
We next tested whether these tumor-specific BTIL31
gd1 T cells could inhibit IL-2 secretion from CD4+ or
Immunity
Tumor-Specific Regulatory gd T CellsFigure 4. BTIL31 gd1 T Cells Function as Treg Cells
(A) Suppression of naive T cell proliferation by BTIL31 gd1 T cells in a functional assay. Proliferation assays were conducted as described in Exper-
imental Procedures.
(B) Functional analysis of gd1 T cells purified from bulk BTILs. gd1 T cells were purified by FACS sorting and used to test for their ability to inhibit naive
T cell proliferation.
(C) BTIL31 gd1 T cells inhibit IL-2 release from CD4+ effector T cells. Anti-CD3 antibody-activated BTIL31 gd1 T cells, T cell clones, or control T cells
were cocultured with CD4+ TIL1363 T helper cells for 24 hr. After washing, all T cells were mixed with 1363 mel tumor cells. IL-2 secretion by CD4+
TIL1363 T helper cells was determined by ELISA after 18 hr incubation. Data from one of three independent experiments with similar results are
shown.CD8+ effector T cells in response to TCR stimulation. As
previously demonstrated (Wang and Wang, 2005), CD4+
T helper TIL1363 cells secreted large amounts of IL-2 after
stimulation with 1363mel tumor cells (Figure 4C). Cocul-
turing with OKT3-pretreated gd1 T cells inhibited IL-2 se-
cretion from the CD4+ T helper TIL1363 cells (Figure 4C), in
contrast to control CD4+ T cells and PBMC-derived gd T
cells, which lacked any inhibitory effect on IL-2 release
by CD4+ effector cells. We also found that gd1 T cells
inhibited IL-2 secretion by CD8+ TIL1359 effector T cells
after stimulation with target 1359mel cells (Figure S2B).
These results suggest that gd1 T cells have a potent abilityto suppress IL-2 production by both CD4+ and CD8+
effector T cells (hereafter termed gd1 Treg cells).
To determine whether BTIL31 gd1 Treg cells share any
phenotypic properties with CD4+ Treg cells, we examined
their cytokine profiles and surface markers. Cytokine pro-
filing analysis showed that these gd1 Treg cells secreted
IFN-g and GM-CSF, but not other cytokines, such as IL-2,
IL-4, IL-10, or TGF-b, when they were stimulated with
either autologous tumor cells or a CD3 antibody (Fig-
ure S3A). To determine whether BTIL31 gd1 Treg cells ex-
press surface markers typically found on CD4+ Treg cells,
we performed both FACS and real-time PCR analyses forImmunity 27, 334–348, August 2007 ª2007 Elsevier Inc. 339
Immunity
Tumor-Specific Regulatory gd T CellsFigure 5. Suppression of DC Maturation and Function by BTIL31 gd1 T Cells
(A) Inhibition of DC maturation by BTIL31 gd1 T cells. The treated and untreated DCs were stained with CD83, CD80, CD86, and HLA-DR antibodies
and analyzed by FACScan.
(B) Inhibition of DC function to secrete IL-6 and IL-12 by BTIL31 gd1 T cells in response to LPS stimulation. Cytokine release is plotted as mean ± SD.340 Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc.
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Tumor-Specific Regulatory gd T CellsCD25, GITR, and Foxp3. BTIL31 gd1 Treg cells were neg-
ative for CD25 and GITR (Figure S3B) and expressed little
or no Foxp3 (Figure S3C), compared with results for pre-
viously characterized CD4+ Treg cells. Thus, BTIL31
gd1 T cells do not share the relatively specific markers
of CD4+ Treg cells.
In addition, we found that BTIL31 gd1 Treg cells could
mediate immune suppression even in a transwell, sug-
gesting that soluble factors are involved in immune sup-
pression (Figure S4A). Indeed, a small amount of cell
supernatant was capable of inhibiting naive T cell prolifer-
ation (Figure S4B). However, neither anti-TGF-b nor IL-10
antibody added in assays affected their suppressive func-
tion (Figure S4C), consistent with their inability to secrete
TGF-b or IL-10. To test whether other cytokines are in-
volved in the suppressive function of BTIL31gd1 Treg cells,
we found that they could secrete IL-6, but not IL-1b, TNF-a,
and IL-12 (Figure S5A). Neither anti-IL-6 nor anti-TNF-a
in a functional assay affected the suppressive function of
gd1 Treg cells (Figure S5B). Thus, these results excluded
the possibility that TGF-b, IL-10, or IL-6 are involved in
the gd1 Treg cell-suppressive function. By using molecular
weight cut-off columns, we found that the suppressive
activity was present in fractions with a molecular mass
larger than 100 kDa and could be inactivated by heat
treatment at 56C for 30 min, but not by DNase or RANase
treatment (data not shown). Taken together, these results
indicate that gd1 Treg cells are functionally distinct from
CD4+ Treg cells.
Tumor-Specific gd1 Treg Cells Impair DCMaturation
and Function
We next asked whether BTIL31 gd1 Treg cells could inhibit
the maturation and function of DCs. Because they medi-
ated immune suppression through soluble factors, we cul-
tured BTIL31 gd1 Treg or control cells in the inner well and
DCs in the outer wells of a transwell plate and then tested
the ability of DCs to mature in the presence of IL-4, GM-
CSF, and TNF-a on the basis of the DC maturation
markers CD83, CD80, CD86, and HLA-DR molecules.
DCs treated with or without naive CD4+ T cells expressed
high amounts of CD83, CD80, CD86, and HLA-DR after
being incubated with the maturation-inducing cytokines
(Figure 5A). In sharp contrast, treatment with BTIL31 gd1
Treg cells blocked DC maturation, in that expression of
all four maturation markers were markedly inhibited. To
test whether BTIL31 gd1 Treg cells could impair the func-
tion of DCs, we treated the DCs with BTIL31 gd1 Treg cells
or naive CD4+ T cells in a transwell plate for 48 hr and then
assessed their ability to respond to LPS. The untreated
mature DCs secreted large amounts of IL-6 and IL-12 in
response to LPS stimulation. In contrast, the release of
both cytokines from DCs markedly decreased after treat-
ment with BTIL31 gd1 Treg cells, whereas treatment withnaive CD4 T cells had no effect on cytokine release by
DCs (Figure 5B).
The ability of DCs to stimulate the proliferation of naive
T cells in response to soluble CD3 antibody is well recog-
nized (Shevach, 2002). To test whether BTIL31 gd1 Treg
cells can inhibit DC stimulation of naive T cell proliferation,
we cocultured naive CD4+ T cells with different numbers
of immature or mature DCs that had been treated with
BTIL31 gd1 Treg cells or left untreated. The untreated
DCs strongly stimulated the proliferation of naive CD4+
T cells, regardless of their maturation status (Figure 5C).
However, neither immature nor mature DCs treated with
BTIL31 gd1 Treg cell culture supernatants could stimulate
naive T cell proliferation; the stimulating ability of DCs
treated with naive CD4+ T cells was not impaired. We con-
clude from these results that BTIL31 gd1 Treg cells not
only can block the maturation of DCs but also can sup-
press their ability to secrete cytokines in response to LPS.
Reversal of gd1 Treg Cell-Suppressive
Function by TLR8 Ligands
Although poly-guanosine (Poly-G) oligonucleotides can
directly reverse the suppressive function of CD4+CD25+
Treg cells (Peng et al., 2005), it was not clear whether
TLR8 ligands could reverse the suppressive function of
gd1 Treg cells. To test this possibility, we treated gd1
Treg cells with a panel of TLR ligands and tested for their
ability to suppress naive T cell proliferation. The TLR8 li-
gands Poly-G3 and ssRNA40, but not ligands for other
TLRs, reversed the suppressive function of BTIL31 gd1
Treg cells and restored the proliferation of naive CD4+ T
cells (Figure 6A). To confirm that Poly-G3 or ssRNA40
treatment restored the cell division of naive T cells, but
not gd1 Treg cells, we cultured BTIL31 gd1 Treg cells
with CFSE-labeled naive CD4+ T cells in the presence or
absence of Poly-G3. After 48 hr, the CFSE-labeled cells
were gated for FACS analysis. Both BTIL31 gd1 Treg and
clones strongly inhibited the cell division of naive CD4+
T cells compared with naive T cells not exposed to gd1
Treg cells, whereas treatment with Poly-G3 oligonucleo-
tides completely restored the cell division of naive T cells
(Figure 6B). Similarly, we also found that treatment of gd1
Treg cells with Poly-G3 oligonucleotides abrogated their
suppressive effects on the maturation and function of
DCs (Figure S6). Thus, these results indicate that Poly-
G3 oligonucleotide treatment not only abolishes the ability
of BTIL31 gd1 Treg cells to suppress T cell proliferation
and function but also abrogates their ability to inhibit DC
maturation and function.
Control of CD8+ T Cell-Mediated Antitumor Immunity
by Tumor-Specific gd1 Treg Cells In Vivo
We next sought to determine whether the gd1 Treg cells
could inhibit antitumor immune responses in a previously(C) Inhibition of the ability of DCs to stimulate naive T cell proliferation in the presence of soluble OKT3 antibody after treatment with BTIL31 gd1 T cells.
Proliferation is plotted as mean ± SD.
Results are representative data from three independent experiments.Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc. 341
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Tumor-Specific Regulatory gd T CellsFigure 6. TLR8 Ligands Reverse the Suppressive Function of BTIL31 gd1 Treg Cells In Vitro and In Vivo
(A) Reversal of suppressive function of gd1 T cells by TLR8 ligands. Relative proliferative activity (%) is plotted as mean ± SD. Proliferative activity of
naive T cells without gd1 T cells serves as a basis (100%) to calculate relative proliferation of naive T cells plus gd1 T cells in the presence of various
TLR ligands. Results are one of three independent experiments.
(B) Restoration of CFSE-labeled naive CD4+ T cell division by Poly-G3 oligonucleotides. CFSE-labeled naive CD4+ T cells were cocultured with
BTIL31 gd1 Treg cells or their clones in the absence or presence of poly-G3 oligonucleotides in OKT3-coated 24-well plates. After 3 days of culture,
cells were harvested and analyzed for cell divisions by FACS gated on the CFSE-labeled cells. CFSE-labeled naive CD4+ T cells alone served as a
control. Data are one of two independent experiments.
(C) Inhibition of antitumor responses by BTIL31 gd1 T cells in NOD-SCID mice. Human 586mel tumor cells were subcutaneously injected into NOD-
SCID on day 0. Tumor-specific CD8+ TIL586 cells were injected i.v. on day 3 with or without OKT3-preactivated BTIL31 gd1 T cells. Tumor volumes
were measured and presented as means ± SD (n = 5 mice per group).
(D) Poly-G reverses the suppressive function of BTIL31 and enhances antitumor immunity in NOD-SCID mice. Experimental procedures and tumor
cell injection were same as in (C) with the exception that OKT3-preactivated gd1 T cells were treated with Poly-G3 or Poly-T10. Tumor volumes were
measured and presented as means ± SD (n = 5 mice per group). p values in (C) and (D) were determined by the one-way analysis of variance (ANOVA).
Similar results were obtained in three repeat experiments.established tumor model (Peng et al., 2005), because Treg
cells can suppress any effector T cells in antigen-nonspe-
cific way once they are activated. When injected alone into
NOD-SCID (NK, T, and B cell-deficient) mice, 586mel
tumor cells showed progressive growth. Tumor growth342 Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc.was inhibited when tumor-bearing mice were treated with
autologous tumor-specific CD8+ TIL586cells,whichcankill
586mel cells (Figure 6C). However, when CD8+ TIL586
cells were coinjected with anti-CD3-preactivated gd1 Treg
cells, gd1 Treg cells inhibited the ability of CD8+ TIL586
Immunity
Tumor-Specific Regulatory gd T Cellscells to kill tumor cells and tumor cells grew progressively
(p = 0.004), suggesting that gd1 Treg cells have the potent
ability to suppress tumor-specific CD8+ T cells in vivo.
To further demonstrate that treatment of gd Treg cells
with Poly-G oligonucleotides can reverse their suppressive
function and restore the antitumor immune response, we
adoptively transferred TIL586 cells and Poly-G3-treated
gd1 Treg cells into tumor-bearing mice. Poly-G treatment
restored the ability of CD8+ TIL586 cells to inhibit tumor
growth (p = 0.01) (Figure 6D). Thus, TLR8 ligand Poly-G
oligonucleotides can reverse the suppressive function of
gd1 Treg cells both in vitro and in vivo.
Critical Molecules Required for the Reversal
of gd Treg Cell Function
We next sought to determine whether TLR8 is expressed
in gd Treg cells by real-time PCR. TLR8 mRNA expression
in gd Treg cells was at least 15-fold higher than that in 293
cells (Figure S7A). Further experiments showed that these
gd Treg cells also expressed TLR1, TLR7, and TLR9, but
weakly or did not express other TLRs (Figure S7B). Be-
cause most TLRs use the common adaptor MyD88 mole-
cule to transduce the signaling from TLR receptors to the
downstream pathway, the critical question is why TLR8
ligands, but not ligands for other TLRs, can reverse the
suppressive function of gd Treg cells. To address this
issue, we constructed a GFP-expressing lentivirus encod-
ing a cDNA for hTLR7 and transduced them into gd Treg
cells. GFP+ (transduced) gd Treg cells were purified by
FACS sorting and then used in a functional assay to de-
termine their ability to respond to TLR7 ligand loxoribine
treatment. Neither TLR7-transduced GFP+ gd Treg cells
nor untransduced cells could respond to loxoribine treat-
ment (Figure 7A), suggesting that activation of TLR7 sig-
naling pathway does not control the suppressive function
ofgdTreg cells. To demonstrate that lenti-hTLR7 construct
was functional, we showed that lenti-hTLR7 constructs
were capable of activating the NF-kB-luc reporter gene
in response to the TLR7 ligand loxoribine (Figure S8A).
Treatment of endogenous TLR7-expressing gd Treg cells
with TLR7 ligand loxoribine also resulted in the transloca-
tion of phosphorylated p65 (NF-kB) into the nucleus (Fig-
ure S8B). Furthermore, we found that the endogenous
TLR7-expressing gd Treg cells did not respond to ligands
for TLR7 and TLR9, but did respond to TLR8 ligands
for their functional reversal (Figure S8C). Taken together,
we conclude that TLR7 signaling is capable of activating
NF-kB pathway but does not control the suppressive
function of gd1 Treg cells.
Based on these results, we reasoned that hTLR8 likely
uses a unique downstream signaling pathway linked to
the control of gd Treg cell function. To test this hypothesis,
we used an siRNA-mediated knockdown approach to
identify critical molecules required for the reversal of Treg
cell function. A panel of GFP-expressing lentivirus-based
U6 promoter-driven shRNA (lenti-shRNA) constructs (four
constructs per gene) was made against IRAK4, TRAF6,
TAK1, IKKa, IKKb, JNK1, JNK2, ERK1, ERK2, and p38a
molecules. By using a previously described approach(Peng et al., 2005), we screened and identified the lenti-
shRNA constructs with the highest knockdown efficiency
for their corresponding target genes by western blot anal-
ysis (Figure S9). The specificity and knockdown efficiency
of the lenti-shRNA constructs were also confirmed in
T cells. Specific knockdown of JNK1, TAK1, and IKKb at
both mRNA and protein levels was observed in T cells
transduced with relevant shRNA, but there was no effect
on irrelevant genes, as shown in Figures S10A and S10B.
We did not observe any effect on target genes when
scrambled shRNAs were used (Figure S10C).
The lenti-shRNAs with the highest knockdown effi-
ciency were selected for the transduction of gd1 Treg cells.
GFP+ (tranduced) and GFP (untransduced) Treg cells
were purified by FACS sorting and used to test for their
ability to respond to Poly-G10 or Poly-T10 oligonucleo-
tides (a control). We found that the knockdown of TLR8,
IRAK4, and TRAF6 in gd Treg cells markedly diminished
their ability to respond to Poly-G10 treatment (Figure 7B).
In contrast, the TAK1 knockdown in GFP+ T cells did not
have any effect, although TAK1 has been implicated to
play a critical role in the TLR signaling pathway (Akira
et al., 2006). Further knockdown experiments with lenti-
shRNA against IKKa, IKKb, JNK1, JNK2, ERK1, ERK2,
and p38a molecules revealed that the knockdown of ei-
ther IKKa or IKKbmolecule resulted in the partial inhibition
of Treg cells to respond to TLR8 ligand treatment, whereas
the RNAi-mediated p38a knockdown completely blocked
Poly-G10-mediated reversal effect on gd Treg cells (Fig-
ure 7C). In contrast, the knockdown of JNK1, JNK2, ERK1,
or ERK2 molecule did not have any effect (Figure 7C).
These results identify a distinct TLR8 signaling pathway
requiring the participation of MyD88, IRAK4, TRAF6,
p38, and IKK molecules, whereas the TAK1, JNK, and
ERK pathways do not appear to be involved in the reversal
of gd Treg cell function.
DISCUSSION
Negative immune regulatory activity at tumor sites has typ-
ically been attributed to CD4+ CD25+ Treg cells, although
recent findings suggest that other T cell subsets can func-
tion as suppressors of antitumor immune responses (She-
vach, 2002; Wang, 2006). In contrast to an earlier study
showing a high percentage of CD4+ CD25+ Treg cells in
the case of breast cancer (Liyanage et al., 2002), we did
not find an increased percentage of CD4+ CD25+ Treg cells
in our TILs derived from breast tumors (data not shown),
which is consistent with a recent report of comparable
numbers of CD4+ CD25+ Treg cells in cancer patients ver-
sus healthy donors (Okita et al., 2005). These observations,
together with data of a dominant CD8aa+ gd1 T cell popu-
lation among breast TILs, led us to postulate a suppressive
role of this T cell subset at tumor sites. In the present study,
we demonstrate that breast- as well as prostate-tumor-
derived TILs contain a dominant gd1 T cell population. Be-
cause currently available gd TCR antibodies do not work
for immunohistochemistry staining, we could not evaluate
the percentage of gd1 T cells in tumor tissues. However,Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc. 343
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Poly-G10 Oligonucleotides
(A) Specificity of TLR8-mediated functional reversal of gd1 Treg cells. TLR7-expressing BTIL31 T cell clones were generated and purified by FACS
sorting. The GFP+ T cells were used to evaluate their ability to respond to different ligands for TLR7 (Loxoribine), TLR8 (Poly-G3), and TLR9 (CpG-B) in
a functional proliferation assay. Data are plotted as means ± SD and are one of three experiments.
(B) Knockdown of TLR8, IRAK4, and TRAF6, but not TAK1, blocked the ability of gd1 Treg cells to respond to Poly-G10 treatment. BTIL31 gd1 Treg
cells were infected with lenti-shRNAs specific for TLR8, IRAK4, TRAF6, and TAK1 molecules, respectively. GFP+ (transduced) and GFP (untrans-
duced) BTIL31 gd1 Treg cells were obtained by FACS sorting and then used to determine their ability to respond to Poly-G10 in functional proliferation
assays. Untransduced BTIL31 gd Treg cells and Poly-T10 served as controls. Proliferative activity of naive T cells without gd1 T cells serves as a basis
(100%) to calculate relative proliferation of naive T cells in the presence of gd1 T cells and various TLR ligands.
(C) Determination of downstream pathways required for TLR8-mediated functional reversal of gd1 Treg cells. Experimental procedures were identical
to those in (B). Untransduced BTIL31 gd1 Treg cells and Poly-T10 served as controls.
Results are representative of three experiments.344 Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc.
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an increased gd1 T cell population (27%–74%) in renal
carcinoma (Choudhary et al., 1995), even though the sup-
pressive function of these gd1 T cells was not reported. In
contrast, by using the same short-term culture condition,
we could not demonstrate a high percentage of gd1 T cells
in melanoma-derived TILs, which are generally dominated
by conventional CD4+ and CD8+ T cell populations. Thus,
we suggest that tumor-infiltrating T cells from epithelium-
derived tumor cells contain a higher proportion of gd1
T cells than do TILs originating in other tissues.
Our findings raise the intriguing question of how gd1
Treg cells are recruited and then expanded in breast tu-
mors. It has been suggested that tumor cells and immune
cells recruit CD4+ Treg cells to tumor sites through cyto-
kine and chemokine attraction (Curiel et al., 2004; Huang
et al., 2006). gd1 Treg cells do not express the CCR4 or
CCR5 receptor (data not shown), so they probably do
not use the same mechanism as CD4+ Treg cells to infil-
trate into tumor sites. Because they naturally reside in ep-
ithelial tissues, gd1 Treg cells can readily traffic in both
normal and malignant epithelium. A plausible mechanism
for the expansion of gd1 Treg cells at tumor sites may be
through direct presentation of antigens by tumor cells. In
our previous studies, we showed that tumor cells express
tumor-specific antigens such as LAGE1 and ARTC1 and
directly stimulate antigen-specific Treg cells (Wang et al.,
2004, 2005). However, our preliminary data (not shown)
indicate that these breast-tumor-derived gd1 Treg cells
cannot recognize the previously identified small nonpep-
tide molecules (Eberl et al., 2004; Hayday, 2000), suggest-
ing that they recognize new and distinct antigens ex-
pressed on autologous tumor cells. Identification of such
tumor antigens may help us to understand how gd1 Treg
cells are activated and maintained at tumor sites.
Although a regulatory role has been suggested for gd T
cells (Pennington et al., 2005), the suppressive function of
human gd1 cells has not been demonstrated thus far. Our
studies with both breast-tumor-derived bulk gd T cell lines
and clones clearly demonstrate a role for gd1 T cells in the
negative regulation of antitumor immunity. They potently
suppress the proliferation and IL-2 secretion of naive/ef-
fector T cells and inhibit DC maturation and function.
More importantly, we found that these breast cancer-
derived gd1 Treg cells inhibit antitumor immune responses
in animal models. Although they share some suppressive
properties with CD4+ CD25+ Treg cells, these tumor-
derived gd Treg cells also possess unique or distinctive
phenotypic and functional features. For example, the tu-
mor-derived gd1 Treg cells do not express CD25 and
Foxp3 markers, which are typically expressed by CD4+
Treg cells, and they suppress immune responses through
a soluble factor-dependent mechanism independent of
IL-10 and/or TGF-b, in contrast to the cell-cell contact-
dependent suppressive mechanism of CD4+ CD25+ Treg
cells. The clear demonstration that murine gd T cells can
‘‘cross-suppress’’ conventional TCRab T cells was re-
cently reported by Pennington et al. (2006), where they
also showed that the suppression by gd T cells does notrequire Foxp3. Hence, epithelial tumor-derived gd1 T cells
represent a unique subset of Treg cells. We are aware that
identification of soluble factors responsible for immune
suppression is critical to a full understanding of the molec-
ular mechanisms by which gd1 Treg cells suppress naive
T cells. Unfortunately, attempts to define such molecules
have so far proved unsuccessful, not only for gd1 Treg
cells but also for more widely studied naturally occurring
CD4+ CD25+ Treg cells. This gap in knowledge under-
scores the need to continue our efforts to identify the mo-
lecular mechaisms of immune suppression mediated by
Treg cells.
The ability of gd1 Treg cells to suppress the function of
both T cells and DCs suggests that their depletion or the
reversal of their suppressive function could enhance anti-
tumor immune responses against breast cancer. Because
gd1 Treg cells do not express a high amount of CD25 mol-
ecules, they could not be eliminated with CD25 antibody
or the IL-2-toxin fusion protein (Ontak). An alternative
would be to manipulate TLR signaling in these Treg cells,
which was shown to reverse the suppressive function of
naturally occurring CD4+ Treg as well as tumor-specific
Treg cells (Peng et al., 2005). Indeed, we found that tu-
mor-derived gd1 T cells express TLR8 ligands and that
treatment with TLR8 ligands can reverse their suppressive
function both in vivo and in vitro, implying that such cells
share a common TLR8 signaling-mediated mechanism
with previously characterized CD4+ Treg cell subsets. In
contrast to our present and previous demonstration of
the unique function of TLR8 signaling (Peng et al., 2005),
human TLR5 has recently been reported to enhance rather
than reverse the suppressive function of CD4+ CD25+ Treg
cells (Crellin et al., 2005). Furthermore, activation of TLR2
with its ligand (Pam3Cys) directly increases the prolifera-
tion of murine Treg cells and temporally reverses their sup-
pressive function (Liu et al., 2006; Sutmuller et al., 2006a).
It should be noted that TLR8 is not functional in mice (Jurk
et al., 2002). Other TLRs such as TLR4 and TLR9 have
been reported to be involved in the control of murine
Treg cell function, mainly through activating DCs by TLR
ligands (Pasare and Medzhitov, 2003), in contrast to hu-
man TLR8 signaling, which directly controls the suppres-
sive function of human CD4+ Treg cells as well as CD8aa+
gd1 Treg cells without DC involvement. These studies in-
dicate that TLR signaling is critically important in control-
ling the suppressive function of Treg cells, but that the
mechanisms of TLR-mediated regulation of Treg cell sup-
pression in humans likely differ from those in mice.
Our functional studies via an RNAi-mediated knock-
down approach revealed that IRAK4 and TRAF6 are criti-
cal for TLR8-mediated reversal of gd1 Treg cells; however,
we unexpectedly found that TAK1 is not required for such
an effect. This hypothesis is supported by an overexpres-
sion study of TLR8 in HEK293 cells, showing that hTLR8
mediates TAK1-independent NF-kB and JNK activation
(Qin et al., 2006), even though such experiments did not
provide information on the functional consequence of this
effect. TAK1 has been demonstrated to play an essential
role in T cell development and survival and is a keyImmunity 27, 334–348, August 2007 ª2007 Elsevier Inc. 345
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antigen-mediated stimulation in T cells (Sato et al., 2006;
Wan et al., 2006) as well as in B cells (Sato et al., 2005).
Thus, although TAK1 is essential for T cell proliferation
and development, it does not appear to be involved in
the TLR8-mediated signaling pathway. These results to-
gether with the published reports suggest unique features
of the TLR8 versus the common TLR signaling pathway.
Because MEKK3 has been suggested to transduce signal-
ing from TRAF6 to p38 and NF-kB activation (Huang et al.,
2004), we are currently evaluating this possibility. In addi-
tion, it is likely that this unique TLR8 signaling pathway
also operates in CD4+ Treg cells. If so, manipulation of
TLR8 signaling pathway through its ligands or drug inhib-
itors of key molecules in this pathway may allow us to shut
off the suppressive function of different subsets of Treg
cells, thus increasing the likelihood to improve therapeutic
potential of cancer vaccines.
EXPERIMENTAL PROCEDURES
Cell Lines and Antibodies
MCF-7 breast-tumor cells and HEK293T cells were obtained from
the American Tissue Culture Collection (ATCC). Melanoma 1359 mel,
1363 mel, and Epstein-Barr virus (EBV)-transformed B cell line
586LCL were obtained from the Surgery Branch, NCI. These lines
were maintained in RPMI 1640 medium containing 10% fetal calf se-
rum (FCS). Breast carcinoma cell lines (BC36, BC31, BC30, and
BC29) and prostate cancer cell lines (PC263 and PC267) were estab-
lished in our laboratory and maintained in keratinocyte medium con-
taining 25 mg/ml bovine pituitary extract, 5 ng/ml epidermal growth
factor, 2 mM L-glutamine, 10 mM HEPES buffer, 2% heat-inactivated
FBS, and penicillin-streptomycin (Invitrogen, Inc. San Diego, CA).
TIL1359-C20 and BTIL-C1 were conventional CD8+ T cell clones capa-
ble of recognizing the corresponding tumor cells in the context of MHC
class I molecules, whereas TIL1358-4B8 comprised CD4+ T cell clones
that recognize an antigen in the context of HLA-DR4 molecules.
Specific anti-human antibodies including anti-CD4, anti-CD8, anti-
CD56, anti-CD16, anti-CD19, anti-CD161, anti-CD25, anti-CTLA-4,
anti-TCRab, anti-TCRgd, anti-CD80, anti-CD83, anti-CD86, and anti-
HLA-DR conjugated FITC or PE, anti-JNK1 were purchased from
R&D Systems and BD Biosciences. TAK1 antibody was purchased
from Cell Signaling Technology. Anti-Vd1 (R9.2), anti-Vd2 (IMMU
389), and anti-Vd9 (IMMU 360) were purchased from Beckman Coul-
ter. Anti-GITR mAb were obtained from R&D Systems. Anti-MHC class
I (HLA-A, B, C; HB95) and anti-class II (HLA-DR, DP, DQ; HB145) were
purified from hybridoma supernatants.
Generation of Tumor-Infiltrating Lymphocytes
and T Cell Cloning
Breast and prostate cancer tissues were minced into small pieces fol-
lowed by digestion with triple enzymes mixture containing collagenase
type IV, hyaronidase, and deoxyribonuclease for 2 hr at room temper-
ature. After digestion, the cells were washed twice in RPMI1640 and
cultured in RPMI1640 containing 10% human serum supplemented
with L-glutamine and 2-mercaptethanol and 1000 U/ml of IL-2 for
the generation of T cells. Once T cells were released from tumor
tissues, they were grown in high-dose IL-2 medium for 1 week. These
T cells were then transferred to a fresh well and grown in low-dose IL-2
(50 U/ml)-containing medium. T cell clones were generated from TILs
by the limiting dilution cloning method, as previously described (Wang
et al., 2004). Tumor-reactive T cell clones were expanded and selected
for further analysis. gd2 T cells were purified from human PBMCs by
sorting after being stained with Vd2 antibody.346 Immunity 27, 334–348, August 2007 ª2007 Elsevier Inc.FACS Analysis and Sorting
The expression of CD25 and GITR on gd T cells was determined by
FACS analysis after staining with specific antibodies (purchased
from R&D Systems and BD Biosciences). To purify the gd T cells, we
stained T cells with a gd antibody conjugated to either PE or FITC. After
washing, the cells were sorted by FACSARIA. For experiments with
carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled cells,
we stained naive CD4+ T cells with CFSE (4.5 mM) from Molecular
Probes at 37C for 15 min. After washing, the labeled cells were cul-
tured in RPMI 1640 containing 10% human AB serum and IL-2 (300
IU/ml). To determine suppression of cell division by BTIL31 gd1 Treg
cells, we added unlabeled gd1 T cells to CFSE-labeled naive T cells
at a 1:1 ratio in OKT3-coated 24-well plates in the presence or absence
of Poly-G3 (3 mg/ml). After 2 days in culture, the cells were analyzed by
FACS gating on the CFSE-labeled cells.
To determine the frequency of gd T cells in the total T cell population
(directly isolated from resected tumor samples without in vitro culture),
we digested breast-tumor samples to obtain single-suspension cells
and then stained them with CD3-FITC and TCRgd-PE antibody.
FACS analysis was conducted after gating on anti-CD3-positive
T cell population.
Proliferation and Cytokine Assays
Proliferation assays were done as previously described (Peng et al.,
2005; Wang et al., 2004). Transwell experiments were performed in
24-well plates with a pore size of 0.4 mm (Corning Costar, Cambridge,
MA) as described previously (Wang et al., 2004). 2 3 105 freshly puri-
fied naive CD4+ T cells were cultured in the outer wells of 24-well plates
in medium containing 0.1 mg/ml anti-CD3 (OKT3) antibody and 23 105
APCs. Equal numbers of gd T cells or naive CD4+ T cells were added
into the inner wells in the same medium containing 0.1 mg/ml CD3 an-
tibody and 2 3 105 APCs. After 56 hr of culture, the cells in the outer
and inner wells were harvested separately and transferred to 96-well
plates. [3H]thymidine was added, and the cells were cultured for an
additional 16 hr before being harvested for counting the radioactivity
with a liquid scintillation counter. All experiments were performed in
triplicate. To determine whether the T cell recognition of autologous tu-
mor cells could be blocked by specific Abs, we assessed T cell activity
in the absence or presence of various Abs as previously described
(Wang et al., 1999).
Suppression Assay for IL-2 Release from CD4+
and CD8+ Effector T Cells
CD3 mAb-activated BTIL31 cells and their clones were cocultured with
CD4+ TIL1363 helper T cells at a 1:1 ratio in RPMI 1640 growth medium
containing 30 IU/ml IL-2 supplemented with 10% human serum for
24 hr. After washing, the treated T cells were cultured with 1363 mel
for another 24 hr. IL-2 secretion in the culture supernatants was deter-
mined by ELISA after 18 hr incubation. Naive CD4+ T cells purified from
human PBMCs were used as controls. Similar experiments were per-
formed for CD8+ TIL1359 effector cells and 1359 mel tumor cells.
Inhibition of DC Maturation and Function by gd1 T Cells
Immature and mature dendritic cells (DCs) were derived from the
monocytes of healthy donors in culture with IL-4 and GM-CSF with
or without TNF-a. The immature DCs or mature DCs were treated
with gd T cells in the transwell system. In brief, 5 3 105 BTIL31 or its
clones were put into the inner wells, and 1 3 106 immature or mature
DCs were cultured in the outer wells of 24-well plates in medium con-
taining IL-4 and GM-CSF with or without TNF-a. After 48 hr, the treated
and untreated DCs were harvested and divided into different groups.
For phenotypic analysis, the surface markers of CD83, CD80, CD86,
and HLA-DR of DCs were analyzed by FACScan (Becton Dickinson).
For cytokine secretion, the treated and untreated DCs were stimulated
with LPS (5 mg/ml) for 24 hr. Release of IL-12 and IL-6 by DCs was mea-
sured by ELISA Kit (R&D System). To determine the ability of DCs to
stimulate the proliferation of allogeneic CD4+ T cells, we cocultured
the gd T cell-treated or untreated immature and mature DCs with naive
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CD4+ T cells.
Toll-like Receptor Ligands and Proliferation Assays
Naive CD4+ T cells were purified from PBMCs by microbeads (Miltenyi
Biotec). Naive CD4+ T cells (105/well) were cultured with regulatory T
cells at a ratio of 10:1 in OKT3 (2 mg/ml)-coated, U-bottomed 96-well
plates containing the following TLR ligands: LPS (100 ng/ml), imiqui-
mod (10 mg/ml), loxoribine (500 mM), poly (I:C) (25 mg/ml), ssRNA40/
LyoVec (3 mg/ml), ssRNA33/LyoVec (3 mg/ml), pam3CSK4 (200 ng/ml),
and flagellin (10 mg/ml), all purchased from Invivogen (San Diego, CA).
CpG-A (3 mg/ml), CpG-B (3 mg/ml), and poly-G3 oligonucleotides (3 mg/
ml) were synthesized by Integrated DNA Technologies (Coralville, IA).
All experiments were performed in triplicate.
Real-Time Quantitative PCR Analysis
Foxp3 mRNA level on gd T cells or CD4+ Treg cells was quantified by
real-time PCR via ABI/PRISM7000 sequence detection system (PE
Applied Biosystems, Foster City, CA) as previously described (Peng
et al., 2005). The PCR reaction was performed with specific primers;
an internal fluorescent TaqMan probe specific to Foxp3 or HPRT
was purchased from PE Applied Biosystems. Foxp3 mRNA level in
each sample was normalized with the relative quantity of HPRT. All
samples were run in triplicate.
Lentivirus-shRNA Constructs and Screening
Three or four shRNA constructs per gene were made. shRNA design,
cloning, and screening were identical to those previously described
(Peng et al., 2005). shRNA constructs with the highest knockdown
efficiency were selected to transduce T cells. To determine the spec-
ificity and knockdown efficiency of lenti-shRNA, we performed similar
experiments for JNK1, TAK1, and IKKb, as previously described (Peng
et al., 2005).
In Vivo Tumor Growth and Antitumor Immunity
Human 586 mel tumor cells (13 106) in 100 ml of buffered saline were
subcutaneously injected into NOD-SCID (lacking T and B cells) on
day 0. Tumor-specific CD8+ TIL586 cells (5 3 106), which recognized
and kill 586mel cells, were i.v. injected on day 3 with or without
BTIL31 cells (1 3 106) pretreated with Poly-G3 or Poly-T10. Tumor
size was measured with calipers every 2–3 days. Tumor volume was
calculated on the basis of two-dimension measurements. All mice
were maintained under specific pathogen-free conditions according
to institutional guidelines and animal study protocols approved by
the institutional animal care and use committees.
Statistical Analysis
Unless indicated otherwise, data are expressed as mean ± SD. The
significance of difference between groups was determined by a one-
tailed Student’s t test or the one-way analysis of variance (ANOVA).
Supplemental Data
Ten figures are available at http://www.immunity.com/cgi/content/full/
27/2/334/DC1/.
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